Alex joined Alchemab as founding CEO in 2019, bringing extensive biotechnology and pharmaceutical leadership experience. He is a serial biotechnology CEO having led Creabilis, a leading European dermatology company, until its acquisition by Sienna Biopharmaceuticals Inc. in December 2016 and more recently being CEO of Zarodex Therapeutics and Camphos Therapeutics.
Alex has 20 years’ experience managing complex research and development projects. Prior to joining Creabilis, he led operations at US-based pain company Solace Pharmaceuticals Inc. Alex gained his R&D experience at Pfizer, where he worked as part of a team that led the restructuring of the company’s global drug development capabilities. He is also a non-executive director and advisor to several organisations.
Alex holds a BEng (Hons) in Mechanical Engineering from the University of Sussex, UK and an MBA from Henley Management College, UK.